359 related articles for article (PubMed ID: 18293418)
21. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
22. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
Bolivar VJ; Manley K; Messer A
Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
[TBL] [Abstract][Full Text] [Related]
23. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
[TBL] [Abstract][Full Text] [Related]
24. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
25. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice.
Nithianantharajah J; Barkus C; Murphy M; Hannan AJ
Neurobiol Dis; 2008 Mar; 29(3):490-504. PubMed ID: 18165017
[TBL] [Abstract][Full Text] [Related]
26. Striatal neurochemical changes in transgenic models of Huntington's disease.
Ariano MA; Aronin N; Difiglia M; Tagle DA; Sibley DR; Leavitt BR; Hayden MR; Levine MS
J Neurosci Res; 2002 Jun; 68(6):716-29. PubMed ID: 12111832
[TBL] [Abstract][Full Text] [Related]
27. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
28. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.
Jenkins BG; Andreassen OA; Dedeoglu A; Leavitt B; Hayden M; Borchelt D; Ross CA; Ferrante RJ; Beal MF
J Neurochem; 2005 Oct; 95(2):553-62. PubMed ID: 16135087
[TBL] [Abstract][Full Text] [Related]
29. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.
Klapstein GJ; Levine MS
J Neurophysiol; 2005 Feb; 93(2):758-65. PubMed ID: 15371492
[TBL] [Abstract][Full Text] [Related]
30. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
31. Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice.
Wood NI; Pallier PN; Wanderer J; Morton AJ
Neurobiol Dis; 2007 Feb; 25(2):342-53. PubMed ID: 17095235
[TBL] [Abstract][Full Text] [Related]
32. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
Freeman W; Morton AJ
Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
[TBL] [Abstract][Full Text] [Related]
33. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
[TBL] [Abstract][Full Text] [Related]
34. Fine-structural analysis and connexin expression in the retina of a transgenic model of Huntington's disease.
Petrasch-Parwez E; Habbes HW; Weickert S; Löbbecke-Schumacher M; Striedinger K; Wieczorek S; Dermietzel R; Epplen JT
J Comp Neurol; 2004 Nov; 479(2):181-97. PubMed ID: 15452853
[TBL] [Abstract][Full Text] [Related]
35. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
36. Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice.
Petersén A; Stewénius Y; Björkqvist M; Gisselsson D
BMC Cell Biol; 2005 Sep; 6():34. PubMed ID: 16159402
[TBL] [Abstract][Full Text] [Related]
37. Slowed progression in models of Huntington disease by adipose stem cell transplantation.
Lee ST; Chu K; Jung KH; Im WS; Park JE; Lim HC; Won CH; Shin SH; Lee SK; Kim M; Roh JK
Ann Neurol; 2009 Nov; 66(5):671-81. PubMed ID: 19938161
[TBL] [Abstract][Full Text] [Related]
38. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
[TBL] [Abstract][Full Text] [Related]
39. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
40. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
